Population per km2 - 487
Innovation Performance Group (2019) : Strong +
Flanders has showcased as a region with great potential in the pharmaceutical market. The region is characterised by exceptionally rapid approval times for clinical trials and puts heavy emphasis on biotech R&D, through a well-developed ecosystem of startups, SMEs and larger international companies. Different strategic research centra (VIB, imec, VITO) focus on aspects related to personalised medicine and work on the valorisation of their research.
Personalised medicine is furthermore one of the priorities in Flanders' smart specialisation strategy. In this light, Flanders is one of the leading regions in the smart specialisation partnership on personalised medicine (S3P4PM) and coordinator of the SAPHIRe project.
Is the region looking for international/European/interregional collaboration opportunities?
Yes - S3 partnerships
Regional level: Vlaamse Beleidsplan Gepersonaliseerde Geneeskunde
Regional level: Vlaanderen in transitie
Regional press release: SAPHIRe
Topics covered In policies : Medical research and innovation (-omics, biomarkers, diagnostics, etc.); Education, training and skill development; Prediction and prevention; ICT/genomics, health, lifestyle data(infrastructure); Electronic and mobile health solutions; Value based healthcare; Public awareness, patient participation with respect to Personalised Medicine/Personalised Health
Policy document (RIS3): Yes
Policy document PM@RIS3: Yes
Antwerpen registry of congenital anomalies - contributes to the EUROCAT network
Digital Innovation Hubs:
Is the region represented in: Horizon2020; Regional Smart Specialisation Strategy Platforms/Partnerships (RIS3); EIT Health/InnoStars/Regional Innovation Scheme (RIS); other?
Organisations in Flanders
European Regions Research and Innovation Network (ERRIN)
By Blank map of Europe (with disputed regions).svg: maix¿?derivative work: Alphathon - This file was derived from: Blank map of Europe (with disputed regions).svg:, CC BY-SA 3.0,